Table 1.
Posterior odds ratios for febrile neutropenia from all cycles with and without the assumption of consistency for lipegfilgrastim vs. pegfilgrastim
| Treatment contrast | Direct OR (95 % CI) | Indirect OR (95 % CI) | p value | Combined (MTC) OR (95 % CI) |
|---|---|---|---|---|
| Lipegfilgrastim vs. pegfilgrastim | 1.00 (0.26–3.79) | 2.00 (0.47–8.11) | 0.76 | 1.39 (0.54–3.50) |